Tags

Type your tag names separated by a space and hit enter

The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.
Eur J Pharmacol. 2011 Jan 10; 650(1):384-9.EJ

Abstract

Although nonalcoholic steatohepatitis (NASH) is associated with insulin resistance partly due to reduced levels of circulating adiponectin, the role of adiponectin receptors including adiponectin receptor 1 and adiponectin receptor 2 in adipose tissues in NASH remains controversial. The present study showed that there was a marked decline in adiponectin receptor 1 and adiponectin receptor 2 expressions in liver and visceral fat, and these expressions were elevated in muscle of NASH rats 12weeks after oral administration of a high-fat diet. An 8-week continuous treatment with rosiglitazone, a peroxisome proliferator-activated receptors γ (PPAR γ) agonist improved the histological lesions markedly in liver of NASH rats, and concurrently increased mRNA and protein expressions of adiponectin receptor 1 and adiponectin receptor 2 in liver and visceral fat, with down-regulation of the two receptors in muscle. There was a negative correlation between the ratio of adiponectin receptors/β-actin protein and serum TNF-α in the liver and visceral fat, and a positive correlation in muscle. Additionally, rosiglitazone increased circulating adiponectin, which was negatively correlated with serum TNF-α. These results indicated that rosiglitazone improved NASH by directly modulating adiponectin receptor 1 and adiponectin receptor 2 in various adipose tissues, or indirectly possibly via decreasing serum TNF-α.

Authors+Show Affiliations

Department of Gastroenterology, Zhabei District Central Hospital, Shanghai 200070, China. liusu2222@163.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20965162

Citation

Liu, Su, et al. "The Ameliorating Effect of Rosiglitazone On Experimental Nonalcoholic Steatohepatitis Is Associated With Regulating Adiponectin Receptor Expression in Rats." European Journal of Pharmacology, vol. 650, no. 1, 2011, pp. 384-9.
Liu S, Wu HJ, Zhang ZQ, et al. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol. 2011;650(1):384-9.
Liu, S., Wu, H. J., Zhang, Z. Q., Chen, Q., Liu, B., Wu, J. P., & Zhu, L. (2011). The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. European Journal of Pharmacology, 650(1), 384-9. https://doi.org/10.1016/j.ejphar.2010.09.082
Liu S, et al. The Ameliorating Effect of Rosiglitazone On Experimental Nonalcoholic Steatohepatitis Is Associated With Regulating Adiponectin Receptor Expression in Rats. Eur J Pharmacol. 2011 Jan 10;650(1):384-9. PubMed PMID: 20965162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. AU - Liu,Su, AU - Wu,Han-Jun, AU - Zhang,Zong-Qi, AU - Chen,Qing, AU - Liu,Bin, AU - Wu,Jian-Ping, AU - Zhu,Liang, Y1 - 2010/10/20/ PY - 2010/03/15/received PY - 2010/09/14/revised PY - 2010/09/20/accepted PY - 2010/10/23/entrez PY - 2010/10/23/pubmed PY - 2011/3/25/medline SP - 384 EP - 9 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 650 IS - 1 N2 - Although nonalcoholic steatohepatitis (NASH) is associated with insulin resistance partly due to reduced levels of circulating adiponectin, the role of adiponectin receptors including adiponectin receptor 1 and adiponectin receptor 2 in adipose tissues in NASH remains controversial. The present study showed that there was a marked decline in adiponectin receptor 1 and adiponectin receptor 2 expressions in liver and visceral fat, and these expressions were elevated in muscle of NASH rats 12weeks after oral administration of a high-fat diet. An 8-week continuous treatment with rosiglitazone, a peroxisome proliferator-activated receptors γ (PPAR γ) agonist improved the histological lesions markedly in liver of NASH rats, and concurrently increased mRNA and protein expressions of adiponectin receptor 1 and adiponectin receptor 2 in liver and visceral fat, with down-regulation of the two receptors in muscle. There was a negative correlation between the ratio of adiponectin receptors/β-actin protein and serum TNF-α in the liver and visceral fat, and a positive correlation in muscle. Additionally, rosiglitazone increased circulating adiponectin, which was negatively correlated with serum TNF-α. These results indicated that rosiglitazone improved NASH by directly modulating adiponectin receptor 1 and adiponectin receptor 2 in various adipose tissues, or indirectly possibly via decreasing serum TNF-α. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/20965162/The_ameliorating_effect_of_rosiglitazone_on_experimental_nonalcoholic_steatohepatitis_is_associated_with_regulating_adiponectin_receptor_expression_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(10)01021-6 DB - PRIME DP - Unbound Medicine ER -